Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) reported Q2 EPS of ($0.43), $0.21 worse than the analyst estimate of ($0.22). Revenue for the quarter came in at $173.91 million versus the consensus estimate of $167.33 million.

For earnings history and earnings-related data on Tarsus Pharmaceuticals, Inc. (TARS) click here.